XML 67 R58.htm IDEA: XBRL DOCUMENT v3.25.1
Collaboration Agreements, License Agreement and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2024
Dec. 31, 2023
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Drug product revenue recognized   $ 29,621 $ 46,803
AstraZeneca Agreements [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Drug product revenue recognized   159,000 89,100
Drug Product Revenue, Net [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Drug product revenue recognized   27,673 18,753
Drug Product Revenue, Net [Member] | Japan [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Drug product revenue recognized $ 14,400    
Drug Product Revenue, Net [Member] | Astellas Agreement [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Drug product revenue recognized   2,000 18,800
Drug Product Revenue, Net [Member] | Astellas Agreement [Member] | Japan [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Drug product revenue recognized   (2,872) 15,656
Drug Product Revenue, Net [Member] | Astellas Agreement [Member] | Europe [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Drug product revenue recognized   4,874 3,097
Drug Product Revenue, Net [Member] | AstraZeneca Agreements [Member] | U.S. [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Drug product revenue recognized   $ 25,671 $ 0